Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Vicari, Luisa ^a   Musumeci, Teresa ^b   Giannone, Ignazio ^b   Adamo, Luana ^a   Conticello, Concetta ^a   De Maria, Ruggero ^a,d   Pignatello, Rosario ^b   Puglisi, Giovanni ^b   Gulisano, Massimo ^a,b,c  

^a Istituto Oncologico del Mediterraneo   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Istituto Superiore di Sanità ^*  (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; NANOSPHERE; PACLITAXEL; POLYGLACTIN; RESOMER; ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SPACE; NANOENCAPSULATION; PARTICLE SIZE; THYROID CANCER; BLOOD DISEASE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; COLLOID; FLUORESCENCE MICROSCOPY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLOIDS; COUMARINS; DRUG CARRIERS; HEMATOLOGIC NEOPLASMS; HUMANS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PACLITAXEL; POLYGLYCOLIC ACID;

EID: 50549084065     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-212     Document Type: Article

References (26)

1. Spratlin J Sawyer MB Pharmacogenetics of paclitaxel metabolism Crit Rev Oncol Hematol 2007, 61:222-9. 10.1016/j.critrevonc.2006.09.006 17092739
2. Gligorov J Lotz JP Preclinical pharmacology of the taxanes: Implications of the differences Oncologist 2004, 9(Suppl 2):3-8. 10.1634/ theoncologist.9-suppl_2-3 15161985
3. Ain KB Egorin MJ De Simone PA Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group Thyroid 2000, 10:587-94. 10958311
4. Chougule PB Akhtar MS Rathore R Koness J McRae R Nigri P Radie-Keane K Kennedy T Wanebo HJ Ready N Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a brown university oncology group phase II study (HN-53) Head Neck 2008, 30(3):289-296. 10.1002/hed.20700 17657799
5. Crown J O'Leary M Ooi WS Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience Oncologist 2004, 9(Suppl 2):24-32. 10.1634/theoncologist.9-suppl_2-24 15161988
6. Galsky MD The role of taxanes in the management of bladder cancer Oncologist 2005, 10:792-8. 10.1634/theoncologist.10-10-792 16314289
7. Haddad R Mahadevan A Posner MR Sullivan C Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer Am J Clin Oncol 2005, 28:104. 10.1097/ 01.coc.0000153282.03031.59 15685044
8. Voigt W Kegel T Weiss M Mueller T Simon H Schmoll HJ Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma J Cancer Res Clin Oncol 2005, 131:585-90. 10.1007/ s00432-005-0673-0 16021466
9. Fonseca C Simoes S Gaspar R Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity J Control Release 2002, 83:273-286. 10.1016/ S0168-3659(02)00212-2 12363453
10. Xie J Wang CH Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel Pharm Res 2005, 22:2079-90. 10.1007/s11095-005-7782-y 16132339
11. Wang YM Sato H Adachi I Horikoshi I Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol Chem Pharm Bull (Tokyo) 1996, 44:1935-40. 8904823
12. Brigger I Dubernet C Couvreur P Nanoparticles in cancer therapy and diagnosis Adv Drug Deliv Rev 2002, 54:631-51. 10.1016/ S0169-409X(02)00044-3 12204596
13. Lacoeuille F Hindre F Moal F Moal F Roux J Passirani C Couturier O Cales P Le Jeune JJ Lamprecht A Benoit JP In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel Int J Pharm 2007, 344:143-9. 10.1016/j.ijpharm.2007.06.014 17646066
14. Stinchcombe TE Nanoparticle albumin-bound paclitaxel: A novel Cremphor-EL-free formulation of paclitaxel Nanomed 2007, 2:415-23. 10.2217/17435889.2.4.415 17716129
15. Zhang Z Feng SS Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release Biomaterials 2006, 27:262-70. 10.1016/ j.biomaterials.2005.05.104 16024075
16. Chacon M Molpeceres J Berges L Guzman M Aberturas MR Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers Eur J Pharm Sci 1996, 8:99-107. 10.1016/S0928-0987(98)00066-9
17. Abdelwahed W Degobert G Stainmesse S Fessi H Freeze-drying of nanoparticles: Formulation, process and storage considerations Adv Drug Deliv Rev 2006, 58:1688-713. 10.1016/j.addr.2006.09.017 17118485
18. Musumeci T Vicari L Ventura CA Gulisano M Pignatello R Puglisi G Lyoprotected nanosphere formulations for paclitaxel controlled delivery J Nanosci Nanotechnol 2006, 6:3118-25. 10.1166/jnn.2006.452 17048526
19. Tirrò E Consoli ML Massimino M Manzella L Frasca F Sciacca L Vicari L Stassi G Messina L Messina A Vigneri P Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells Cancer Res 2006, 66:4263-72. 10.1158/ 0008-5472.CAN-05-3248 16618750
20. Are C Shaha AR Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches Ann Surg Oncol 2006, 13:453-64. 10.1245/ASO.2006.05.042 16474910
21. Mu L Feng SS A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS J Control Release 2003, 86:33-48. 10.1016/S0168-3659(02)00320-6 12490371
22. Hennenfent KL Govindan R Novel formulations of taxanes: A review. Old wine in a new bottle? Ann Oncol 2006, 17:735-49. 10.1093/annonc/mdj100 16364960
23. Sinha R Kim GJ Nie S Shin DM Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery Mol Cancer Ther 2006, 5:1909-17. 10.1158/1535-7163.MCT-06-0141 16928810
24. Feng S Huang G Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers J Control Release 2001, 71:53-69. 10.1016/S0168-3659(00)00364-3 11245908
25. Bennis S Chapey C Couvreur P Robert J Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture Eur J Cancer 1994, 30A:89-93. 10.1016/S0959-8049(05)80025-5 8142172
26. Chavanpatil MD Patil Y Panyam J Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux Int J Pharm 2006, 320:150-6. 10.1016/j.ijpharm.2006.03.045 16713148